Biohaven(NYSE) BHVN

Biohaven makes medicines for people with brain and immune system diseases. These drugs help patients who need better treatment options. The company finds new ways to slow down serious diseases.

Medicine for Brain and Immune Disorders

• Kv7 Ion Channel Modulation: Therapies for epilepsy and mood disorders that regulate the electrical activity of brain cells.
• MoDE and TRAP Degraders: Bispecific molecules designed to remove disease-causing proteins from the blood and move them to the liver for disposal.
• Myostatin-Activin Target Agents: Treatments for muscle-wasting diseases and obesity that aim to build muscle and reduce body fat.

Key Deals and Partnerships

• Acquired the Channel Biosciences drug platform in February 2022 to target specific ion channels in the nervous system.
• Licensed taldefgrobep alfa from Bristol Myers Squibb in February 2022 to develop treatments for neuromuscular conditions and obesity.
• Partnered with Ypsomed in late 2024 to manufacture an autoinjector for patients to self-administer medicine.
• Collaborated with the Global Coalition for Adaptive Research in July 2022 to evaluate treatments for brain cancer.

What Makes the Technology Different?

Biohaven uses proprietary drug development platforms to target biological pathways, such as moving harmful proteins to the liver to be broken down. The company prioritizes late-stage clinical trials while reducing costs in earlier-stage research to focus financial resources on programs with the most potential value.

Important Financial Facts for 2025

• Net income loss was $145.6 million in Q4 2025, up 22.1% (narrowed — improved) year-over-year.
• Operating income loss hit $142.7 million in Q4 2025, up 24.8% (narrowed — improved) from the prior year.
• Free cash flow loss totaled $130.7 million in Q4 2025, up 23.5% (narrowed — improved) from Q4 2024.
• Market cap hit $1.4 billion in Q4 2025, down 64% from $3.8 billion in Q4 2024.
• Revenue was $0 for the fiscal year ended December 31, 2025, as the company is still in the clinical stage.

Looking at the Big Picture

Biohaven has evolved into an independent biopharmaceutical company focused on bringing late-stage neurological and immunological treatments to market. The company’s long-term progress depends on successfully advancing its high-priority clinical programs through regulatory review.